Novamind Company Information
|Industry||Medical Care Facilities|
|Headquarters||10 Wanless Ave Suite 201|
Toronto, ON, Canada.M4N 1V6
|Phone||+1 (647) 953 9512|
Novamind was founded in 2019 in an effort to create a company that will build a worldwide network of infrastructure that enhances the psychedelic industry.
The company has two divisions, namely Cedar Psychiatry and Cedar Clinical Research, to provide legal, safe, functional, and result-oriented psychedelic experiences. Through the divisions, it also plans to conduct research and development that advances psychedelic medicine.
A year after the company was founded, it appointed a thought leader in psychedelic medicine. Reid Robinson is a renowned researcher and clinician who has made significant contributions towards offering better and effective psychedelic-assisted psychotherapy in psychiatry.
With the looming psychedelic renaissance, more inventions are being created, and scientists are keen on bringing evidence-supported principles and psychedelic medicine to transform people’s lives globally.
Novamind is determined to create a global network of clinical research sites, therapeutic clinics, and retreats in order to facilitate safe access to psychedelic medicine.
To facilitate safe, legal access to psychedelics.
A new standard of mental healthcare
Provide access to medicine for everyone, including the marginalized groups in the society.
Create and conduct advanced research on novel mental treatments
Responsible management of psychedelics in healthcare
Become an inclusive company that performs collaborations with indigenous groups, non-profits, and academic groups
Novamind Stock IPO
Towards the end of 2020, Hinterland metals and Novamind announced the finalization of the deal to amalgamate. The agreement replaced the previously signed letter of intent.
Through the deal, Novamind became a wholly-owned subsidiary of Hinterland. The two companies merged and took up the name Novamind Inc.
Novamind Inc adopted the ticker symbol NM and has since begun trading on the Canadian Securities Exchange (CSE) since the 5th of January 2021.
Novamind Inc divisions
This is an outpatient medical center that focuses on offering different psychedelic treatments. The specialists direct their effort towards furthering innovations in psychedelic medicine.
These treatments include:
Ketamine has shown great promise as an antidepressant that offers instant relief. The brand seeks to boost the effects’ duration by coupling the ketamine treatments with psychotherapy.
Transcranial Magnetic Stimulation TMS
Though approved for the treatment of OCD and depression, TMS can make great strides with other conditions.
This noninvasive medical treatment involves brain rewiring through the use of magnetic pulses.
This treatment option involves combining an oral depressant with spravato, a derivative of ketamine that is FDA approved.
Cedar clinical research
The division focuses on conducting research that fosters mental health breakthroughs. It offers the following clinical services: